Intellia Therapeutics heads into the final week of September with a striking contradiction at its core: nearly 40% of the float is shorted, yet options traders are the most bullish they have been all year. Short interest is the dominant feature of this stock's positioning. Nearly 40% of the free float — 45.8 million shares — is currently sold short, a level that has barely moved in…
Key data as of 10 Nov 2026
Intellia Therapeutics reports after the close on May 14 with more than a third of its free float sold short — a level that makes the lending market the most important context for tomorrow's print. Short interest has…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NTLA — free to start on ORTEX.
Sign up for free →Open NTLA on ORTEX